Track topics on Twitter Track topics that are important to you
WILMINGTON, Del., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Ryland Group, Inc. (“Ryland” or the “Company”) relating to the sale of the Company to Standard Pacific Corp. (“Standard Pacific”). On June 14, 2015, the two companies announced the signing of a definitive merger agreement pursuant to which Standard Pacific will acquire Ryland in a merger worth $5.2 billion. As a result of the merger, Ryland shareholders are only anticipated to receive 1.0191 common shares of Standard Pacific (equivalent to $42.59 per share) in exchange for each share of Ryland.
Andrews & Springer’s investigation focuses on the inadequate consideration that Ryland shareholders are expected to receive. While the deal is advertised as offering a premium for Ryland shareholders, the consideration is below the target prices of eight (8) analysts spanning from Evercore ISI’s April 14, 2015 $55.00 price target to MKM Partners’ January 30, 2015 $43.00 price target. Moreover, the 1.0191 fixed exchange ratio restricts the value that Ryland shareholders are expected to receive by exposing shareholders to the volatility of Standard Pacific’s share price. Following the merger, Ryland shareholders are expected to be substantially diluted, owning only 41% of the combined company. The process leading up to the announcement of the merger also appears to have significant conflicts of interest, thus making the process and consideration unfair. At least five (5) directors from Ryland are anticipated to be joining the board of directors of the combined company after the consummation of the merger.
If you own shares of Ryland and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/ryland-group-class-action-investigation or contact Craig J. Springer, Esq. at email@example.com, or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – www.linkedin.com/company/andrews-&-springer-llc, Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.
Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.
Contact: Craig J. Springer, Esq. firstname.lastname@example.org Call Toll Free: 1-800-423-6013NEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...